Incyte (INCY) Misses Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Incyte (INCY) Price Target Lifted to $107 at Brean Capital; 'Broad And Robust Pipeline'
April 30, 2015 12:34 PM EDTBrean Capital analyst Jonathan Aschoff reiterated a Buy rating and boosted his price target on Incyte (NASDAQ: INCY) to $107.00 (from $84.00), citing a broad and robust pipeline.
Aschoff commented, "US Jakafi sales of $115.3 million included meaningful contribution from PV and beat consensus of $112.4 million. Ex-US Jakafi royalties of $15.7 million slightly missed consensus of $16.1 million. The 9% QoQ increase in Jakafi net sales was driven by 8% unit... More
Incyte's (INCY) Hodgkin Lymphoma Treatment Receives FDAOrphan Drug Designation
April 30, 2015 9:07 AM EDTIncyte (NASDAQ: INCY) received orphan drug Designation for treatment of Hodgkin lymphoma. The FDA site on the designation is here.
... More